

*Citation for published version:*

Jiang, J-H, Bhuiyan, MS, Shen, H-H, Cameron, DR, Rupasinghe, TWT, Wu, C-M, Le Brun, AP, Kostoulas, X, Domene, C, Fulcher, AJ, McConville, MJ, Howden, BP, Lieschke, GJ & Peleg, AY 2019, 'Antibiotic resistance and host immune evasion in *Staphylococcus aureus* mediated by a metabolic adaptation', *Proceedings of the National Academy of Sciences of the United States of America*, vol. 116, no. 9, pp. 3722-3727.  
<https://doi.org/10.1073/pnas.1812066116>

*DOI:*

[10.1073/pnas.1812066116](https://doi.org/10.1073/pnas.1812066116)

*Publication date:*

2019

*Document Version*

Peer reviewed version

[Link to publication](#)

*Publisher Rights*

CC BY-NC

This is the author accepted manuscript of an article published in final form in PNAS, and available online via:  
<https://doi.org/10.1073/pnas.1812066116>. (C) 2019 PNAS.

**University of Bath**

**Alternative formats**

If you require this document in an alternative format, please contact:  
[openaccess@bath.ac.uk](mailto:openaccess@bath.ac.uk)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

**Antibiotic resistance and host immune evasion in *Staphylococcus aureus*  
mediated by a novel metabolic adaptation**

Jhih-Hang Jiang<sup>a,1</sup>, Md Saruar Bhuiyan<sup>a,1</sup>, Hsin-Hui Shen<sup>b,1</sup>, David R. Cameron<sup>a</sup>,  
Thusitha Rupasinghe<sup>c</sup>, Chun-Ming Wu<sup>d</sup>, Anton P. Le Brun<sup>e</sup>, Xenia Kostoulas<sup>a</sup>,  
Carmen Domene<sup>f</sup>, Alex J. Fulcher<sup>g</sup>, Malcolm J. McConville<sup>h</sup>, Benjamin P. Howden<sup>i</sup>,  
Graham J. Lieschke<sup>j</sup> and Anton Y. Peleg<sup>a,k,2</sup>

<sup>a</sup>*Infection and Immunity Program, Monash Biomedicine Discovery Institute and  
Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia*  
<sup>b</sup>*Department of Materials Science and Engineering, Faculty of Engineering, Monash  
University, Clayton, Victoria 3800, Australia*

<sup>c</sup>*Metabolomics Australia, Bio21 Institute of Molecular Science and Biotechnology,  
Parkville, Victoria 3010, Australia*

<sup>d</sup>*National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan*

<sup>e</sup>*Australian Centre for Neutron Scattering, Australian Nuclear Science and  
Technology Organisation, Locked Bag 2001, Kirrawee DC, New South Wales 2232,  
Australia*

<sup>f</sup>*Department of Chemistry, University of Bath, Claverton Down, Bath, United  
Kingdom*

<sup>g</sup>*Monash Micro Imaging, Monash University, Clayton, Victoria 3100, Australia*

<sup>h</sup>*Department of Biochemistry and Molecular Biology, Bio21 Institute of Molecular  
Science and Biotechnology, University of Melbourne, Parkville, Victoria 3010,  
Australia*

<sup>i</sup>*Melbourne Diagnostic Unit, University of Melbourne, Melbourne, VIC, Australia*

<sup>j</sup>*Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria  
3800, Australia*

<sup>k</sup>*Department of Infectious Diseases, The Alfred Hospital and Central Clinical School,  
Monash University, Melbourne, Victoria 3004, Australia*

**Short title: Lipid membrane evasion mechanism of *S. aureus***

<sup>1</sup>These authors contributed equally to this work.

<sup>2</sup>**Corresponding author:** Anton Y. Peleg, Department of Infectious Diseases, The

34 Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria  
35 3040, Australia. Email: [anton.peleg@monash.edu](mailto:anton.peleg@monash.edu) Tel: +61 3 90768491 Fax: +61 3  
36 90762431  
37 *Classification:* Biological Sciences/Microbiology  
38

## Abstract (196/250)

*Staphylococcus aureus* is a notorious human bacterial pathogen with considerable capacity to develop antibiotic resistance. We have observed that human infections caused by highly-drug resistant *S. aureus* are more prolonged, complicated and difficult to eradicate. Here, we describe a novel metabolic adaptation strategy used by clinical *S. aureus* strains that leads to resistance to the last-line antibiotic, daptomycin, and simultaneously impacts host innate immunity. This response was characterized by a change in anionic membrane phospholipid composition induced by point mutations in the phospholipid biosynthesis gene, *cls2*, encoding cardiolipin synthase. Single *cls2* point mutations were sufficient for daptomycin resistance, antibiotic treatment failure and persistent infection. These phenotypes were mediated by enhanced cardiolipin biosynthesis, leading to increased bacterial membrane cardiolipin and reduced phosphatidylglycerol. The changes in membrane phospholipid profile led to modifications in membrane structure that impaired daptomycin penetration and membrane disruption. The *cls2* point mutations also allowed *S. aureus* to evade neutrophil chemotaxis, mediated by the reduction in bacterial membrane phosphatidylglycerol, a previously undescribed bacterial-driven chemoattractant. Together, these data illustrate a novel metabolic strategy used by *S. aureus* to circumvent antibiotic and immune attack, and provide crucial insights into membrane-based therapeutic targeting of this troublesome pathogen.

**Keywords:** *S. aureus*, daptomycin, cardiolipin, phosphatidylglycerol, neutrophils

61 **Significance Statement (109/120)**

62 *Staphylococcus aureus* is one of the most significant human bacterial pathogens that  
63 has the capacity to cause serious infections and become highly resistant to antibiotics.  
64 In this study, we identified a metabolic adaptation mechanism used by *S. aureus* to  
65 simultaneously circumvent killing by one of the last-line anti-staphylococcal antibiotics,  
66 daptomycin, and attack from host innate immune cells. This process led to enhanced  
67 bacterial survival and was mediated by a change in bacterial membrane phospholipid  
68 composition sufficient to impair daptomycin membrane penetration and significantly  
69 impact neutrophil chemotactic responses. These results highlight the importance of  
70 bacterial membrane lipid adaptation in bacterial pathogenesis, and provide crucial  
71 insights into potentially novel therapeutic targeting.

\body

## Introduction

*Staphylococcus aureus* is one of the most important human bacterial pathogens, with a worldwide distribution and an ability to cause infection of almost any human tissue (1). Effective treatment of staphylococcal infections has been hampered by the emergence of antibiotic resistance, leading to increased reliance on last-line antibiotics such as daptomycin (2). Daptomycin is a cyclic lipopeptide antibiotic that interacts with bacterial cell membranes but the precise mechanisms of action remain elusive (3). Notably, human infections caused by daptomycin-resistant *S. aureus* have been associated with persistent and complicated infections (2, 4). We and others have recently shown that clinically-derived daptomycin-resistant isolates caused persistent infections in non-mammalian and murine septicemia models (5, 6), raising the question about the correlation between daptomycin resistance, immune evasion and bacterial survival *in vivo* (5, 6).

Bacteria have evolved highly conserved mechanisms mediating adaptation and maintenance of membrane integrity to defend against host microbicidal peptides (7, 8). Mutations in genes related to phospholipid biosynthesis are consistently reported in Gram-positive bacteria resistant to daptomycin (4). The most abundant phospholipid found in Gram-positive bacterial membranes, including staphylococcal membranes, is phosphatidylglycerol (PG). PG can be converted to cardiolipin (CL) and lysyl-phosphatidylglycerol (L-PG) by the enzymes cardiolipin synthase (Cls) and multiple peptide resistance factor (MprF), respectively (9-11). Gain-of-function mutations in MprF have been associated with daptomycin resistance (8, 9, 12). Most human bacterial pathogens have a Cls homolog that catalyzes condensation of two PG molecules to yield one CL and one glycerol molecule (13). In *S. aureus*, there are two *cls* genes, with

*cls2* encoding the major CL synthase (10, 11). Thus far, the bacterial membrane adaptation response to antibiotic and innate immune exposure in humans is poorly understood.

Neutrophils form one of the most fundamental host innate immune effectors against bacterial pathogens, including *S. aureus* (14). The clinical significance of neutrophils is well illustrated by the predisposition to severe and recurrent staphylococcal infections in patients with functional or quantitative neutrophil deficiencies (15). Neutrophil recruitment to the site of infection caused by Gram-positive bacteria is often mediated by bacterial-driven chemoattractants such as formylated peptides and phenol soluble modulins, or by endogenous cytokines (eg. IL-8) released from host cells (16, 17). In response, bacteria have evolved mechanisms that interfere with neutrophil chemotaxis, including chemotaxis inhibitory protein of *S. aureus* (CHIPS) and formyl peptide receptor-like 1 inhibitor (FLIPr) (18, 19). Deepening our understanding of how bacteria evolve during human infection to simultaneously circumvent key innate immune effectors and antibiotic selection pressure is crucial in our pursuit of novel therapeutic strategies.

## RESULTS

### **Mutations in *S. aureus* cardiolipin synthase lead to the evolution of daptomycin resistance and antimicrobial failure**

We have previously collected and reported on *S. aureus* isolates from nine patients with bloodstream infection who were all treated with daptomycin (4). Samples were collected as soon as the infection was detected and later in infection when resistance to daptomycin and treatment failure was evident (4). All patients had persistent bacteremia and complicated infections involving heart valves, bone and joints, and deep soft-tissues (4). Whole genome sequencing of the nine paired samples identified non-synonymous point mutations in *cls2* in daptomycin-resistant isolates, which were tightly positioned in the two predicted N-terminal transmembrane domains encoded by *cls2*, resulting in A23V, T33N, L52F and F60S amino acid substitutions (Fig. 1A) (4). To study these nucleotide changes in *cls2*, independent of other mutations observed in the clinical daptomycin-resistant strains, allelic replacement experiments were performed to introduce the individual point mutations into a daptomycin-susceptible clinical isolate (A8819) producing A8819<sub>Cls2A23V</sub>, A8819<sub>Cls2T33N</sub> and A8819<sub>Cls2L52F</sub> (Table S1). Several attempts to generate the F60S substitution were unsuccessful. Daptomycin susceptibility was most perturbed with the T33N mutation (A8819<sub>Cls2T33N</sub>), which led to a minimum inhibitory concentration (MIC) of daptomycin similar to that observed in our clinical resistant isolates (MIC 2 µg/ml) compared to the susceptible parent strain (MIC 0.5 µg/ml) (Table S1). This magnitude rise in MIC of daptomycin has been associated with therapeutic failure and poor patient outcomes (2), confirming the significance of the increase. Chromosomal repair of the T33N mutation (A8819<sub>Cls2T33NN33T</sub>) restored daptomycin susceptibility back to wild-type levels (MIC 0.5 µg/ml) (Table S1). L52F and A23V mutations also increased MICs of daptomycin



but to a lesser degree (up to 1 µg/ml) (Table S1).

To assess the functional impact of the reduced daptomycin susceptibility with the *cls2* mutations, we performed daptomycin treatment assays (Fig. 1B). Daptomycin concentrations (2 µg/ml and 4 µg/ml) were chosen to mimic free daptomycin concentration observed in deep tissues and bones under standard human dosing (20, 21). Using a concentration of 2 µg/ml, we showed that daptomycin was rapidly bactericidal ( $\geq 3 \log_{10}$  reduction in colony forming units [CFU]) against all strains over 8 hours, however significant regrowth occurred back to the starting inocula by 24 hours for A8819<sub>Cls2T33N</sub> and A8819<sub>Cls2L52F</sub> (Fig. 1B). In contrast, killing to undetectable levels was seen for the daptomycin-susceptible parent strain (A8819) and the T33N repaired strain (A8819<sub>Cls2T33NN33T</sub>). Similar findings were observed with daptomycin concentrations up to 4 µg/ml (Fig. S1). Daptomycin treatment failure with A8819<sub>Cls2T33N</sub> and A8819<sub>Cls2L52F</sub> directly correlated with progressive resistance, with an MIC of daptomycin increasing up to 4 µg/ml, suggesting that additional adaptation occurred under daptomycin exposure (Fig. 1C). Together, these data show that as seen in patients, the observed *cls2* point mutations genetically predisposed *S. aureus* to resistance evolution and therapeutic failure under antibiotic selection.

### **Amino acid substitutions in *S. aureus* cardiolipin synthase enhance cardiolipin biosynthesis and alter bacterial membrane phospholipid composition**

To determine the impact of the clinically derived *cls2* point mutations on membrane phospholipid composition, we extracted total lipids from the daptomycin-susceptible clinical strain (A8819), the three *cls2* point mutants (A8819<sub>Cls2T33N</sub>, A8819<sub>Cls2A23V</sub>, A8819<sub>Cls2L52F</sub>) and the repaired strain (A8819<sub>Cls2T33NN33T</sub>). We first assessed lipid profiles using thin-layer chromatography (Fig. S2A), which showed that relative to

A8819, the three *cls2* point mutants had an increase in membrane CL content and a reduction in PG, with no change in L-PG. A time-course lipid analysis over bacterial growth phases supported these findings (Fig. S2B, C). The concentration of individual phospholipid species was then quantified using liquid chromatography coupled with mass spectrometry (LC-MS). Consistent with the TLC analysis, the percentage of CL among total phospholipids increased significantly in the three *cls2* point mutants compared to A8819, whereas the PG content decreased significantly (Fig. 2A). None of the *cls2* mutations impacted on L-PG. Overall, the membrane phospholipid changes were most pronounced for A8819<sub>Cls2T33N</sub> (Fig. 2A), which paralleled the magnitude of daptomycin resistance. Importantly, as seen with daptomycin susceptibility, repair of the T33N mutation restored the membrane phospholipid profile back to wild-type levels (Fig. 2B and Fig. S2D). The increase in CL in the *cls2* point mutants was not secondary to an increase in *cls2* transcription or Cls2 membrane quantity, and Cls2 membrane localization was unchanged compared to A8819 (Fig. S3A-C).

To test whether the *cls2* mutations increased cardiolipin synthesis activity *in vivo*, bacteria were metabolically labelled with <sup>13</sup>C-glycerol, which is incorporated into the glycerol backbone and head group of PG and CL (Fig. S4A-C). The formation of complex PG or CL mass isotopomers (+3, +6 and +9) by LC-MS can then be used to measure *de novo* biosynthesis of these phospholipids (Fig. S4A-C). Compared to wild-type, we showed that CL biosynthesis significantly increased over time in our T33N mutant strain (Fig. 2C) and this was mirrored by a reduction in PG biosynthesis (Fig. 2D). Given that PG is both a metabolic end-product and precursor for CL, these results suggest that CL is synthesized from a sub pool of PG in the mutant to account for the different degree of <sup>13</sup>C-labelling. No difference in biosynthesis of L-PG was observed (Fig. 2E). Together, these data confirm that clinically relevant Cls2 amino acid

substitutions caused enhanced membrane cardiolipin biosynthesis that was proportional to the degree of antibiotic resistance.

### **Changes in *S. aureus* membrane composition blocks daptomycin mediated lipid extraction, membrane penetration and disruption**

To assess the impact of Cls2-mediated lipid changes on daptomycin-membrane interactions, we reconstituted Gram-positive bacterial bilayer membranes immobilised on a planar surface for characterization by neutron reflectometry (NR) (22, 23) (Fig. S5A). The bilayers were incubated with isotopic solvents (D<sub>2</sub>O and H<sub>2</sub>O) and the NR profiles of wild-type and A8819<sub>Clis2T33N</sub> were modelled simultaneously to analyze the bilayer structures (Fig. 3A-B). The cardiolipin-rich membrane caused by the Cls2 T33N amino acid substitution was thicker compared to the wild-type membrane ( $57.8 \pm 3.7$  Å versus  $49.4 \pm 3.3$  Å, respectively) (Fig. S5B, Table S2-3, Fig. 3C-D). Despite the overall differences in membrane thickness, the cell surface charge was similar, and using super-resolution microscopy of cell surface bound fluorescent daptomycin, we showed that the level and distribution of daptomycin binding on A8819<sub>Clis2T33N</sub> cell surface was similar to A8819 (Fig. S6A-D). These data support the hypothesis that structural modification of the membrane impairs daptomycin penetration and membrane disruption rather than initial binding.

Using NR, we then characterised the impact of the observed membrane changes on daptomycin interactions. Daptomycin treatment at 2, 4 and 8 µg/ml significantly shifted the fringe of the NR curves of the wild-type membranes in a concentration dependent manner (Fig. 3A. arrows), indicating extraction and solubilisation of the membrane by daptomycin. In contrast, there was a less pronounced change in reflectivity for the cardiolipin-rich, daptomycin-resistant A8819<sub>Clis2T33N</sub> membrane (Fig. 3B). Analysis of

the NR curves showed that at a daptomycin concentration of 2  $\mu\text{g/ml}$ , the lipid volume fraction of the wild-type membrane was reduced, and no daptomycin was seen within the membrane consistent with a lipid extraction mechanism (24) (Table 1, Table S4). At a higher daptomycin concentration (4  $\mu\text{g/ml}$ ), antibiotic membrane penetration was evident, extending through the bilayer and causing dislocation of acyl-chains (Table 1, Table S4). At the highest concentration (8  $\mu\text{g/ml}$ ), the membrane was completely solvated by daptomycin, with a substantial decrease in the lipid volume fraction from 86.5% to 26.6% (Table 1, Table S4). For the thicker, cardiolipin rich, A8819<sub>Cl<sub>s</sub>2T<sub>33</sub>N</sub> membrane, only mild lipid extraction was observed at 2, 4 and 8  $\mu\text{g/ml}$  with the lipid volume fraction only reducing from 78.5% to 62.8% (Table 1, Table S5). The A8819<sub>Cl<sub>s</sub>2T<sub>33</sub>N</sub> membrane resisted daptomycin penetration and remained intact (Table 1, Table S5).

To further define the daptomycin-membrane interaction, we then used small-angle neutron scattering (SANS), which provided information on the daptomycin aggregation characteristics within the bilayer membranes under physiologically relevant conditions (25). Consistent with our NR data, at a clinically relevant daptomycin concentration of 4  $\mu\text{g/ml}$ , we observed daptomycin penetrate and form aggregates straddling the bilayer membrane for wild-type (A8819) but not for the A8819<sub>Cl<sub>s</sub>2T<sub>33</sub>N</sub> membranes (Fig. 3E, and F). These data also concur with our bacterial killing data, which showed complete bacterial killing for wild-type A8819 but therapeutic failure toward A8819<sub>Cl<sub>s</sub>2T<sub>33</sub>N</sub> (Fig. S1). Using established core-shell and hollow-cylinder models to characterise the daptomycin aggregates (25), it was estimated that daptomycin constituted a  $28 \pm 0.86$  Å radius spherical micelle structure within the membrane bilayer (Fig. S7). Taken together, these results show that *S. aureus* adapts during treatment with daptomycin in human infections by increasing its cardiolipin membrane content leading to a thicker

membrane that resists daptomycin lipid extraction, and membrane penetration and disruption, promoting bacterial survival.

## **Cls2 amino acid substitutions impair neutrophil recruitment *in vivo* and promote bacterial survival**

Apart from impairing daptomycin-membrane interactions, we hypothesised that the altered bacterial membrane phospholipid profile caused by *cls2* point mutations may impact on *S. aureus* – host interactions. Neutrophils are the dominant innate immune cell for controlling *S. aureus* infection (14, 15). To interrogate neutrophil behaviour *in vivo* and in real-time with high resolution, we utilised the vertebrate zebrafish (*Danio rerio*) model system (26). In common with humans, zebrafish have cellular and soluble immune arms, and complex tissue environments that enable a mechanistic understanding of human infectious diseases (26, 27). To assess neutrophil trafficking and recruitment to a localized soft tissue staphylococcal infection, we used transgenic embryos with red fluorescent neutrophils (Tg[*lyz*:dsRed]) (28) that were infected into the somatic muscle with GFP-expressing *S. aureus* (Fig. 4A). Notably, neutrophil recruitment to the localized infection site was significantly compromised for infection with the three *cls2* point mutants compared to infection by A8819 after 6 hours post-infection (Fig. 4B,C). Mutation repair for the T33N strain (A8819<sub>CLS2T33NN33T</sub>) was sufficient to restore neutrophil recruitment back to wild-type (A8819) infection levels (Fig. 4D). This attenuated neutrophil response impacted bacterial clearance, with more persistent infection observed with A8819<sub>CLS2T33N</sub> compared to the wild-type and repaired strains (Fig. 4E). To further validate the observed neutrophil migration findings in zebrafish, we assessed human neutrophil migration within an ex-vivo assay. As shown in Fig. 4F, significantly less human neutrophil recruitment was observed with A8819<sub>CLS2T33N</sub> compared to the wild-type strain. Mutation repair of the T33N mutant

(A8819<sub>ClS2T33NN33T</sub>) caused similar neutrophil recruitment as wild-type (Fig. 4F). These results indicated that the Cls2 amino acid substitutions equipped *S. aureus* with the ability to circumvent neutrophil recognition and response, leading to a persistent infection as observed in patients and animal models (2, 5, 6).

#### **Compositional changes of membrane phospholipids resulted in reduced neutrophil recruitment in zebrafish**

To investigate the contribution of the *S. aureus* bacterial membrane to neutrophil evasion, total lipids were extracted from each of the *cls2* mutant and the daptomycin-susceptible parent (A8819) and repaired strains. Liposomes were then processed and injected into the otic vesicle of zebrafish (Fig. 4A, white circle). The otic vesicle is normally devoid of leukocytes and is relatively confined, preventing dispersion of the liposomes (29). As shown in Fig. 5A, and similar to that seen with infection of live, whole bacterial cells (Fig. 4B-D), the liposomes from the three *cls2* point mutants were significantly attenuated in inducing neutrophil recruitment compared to liposomes from A8819 and the T33N repaired strain (A8819<sub>ClS2T33NN33T</sub>), suggesting that altered anionic phospholipid composition may be responsible for the immune evasion. To determine the phospholipid driver of this *S. aureus* evasion response, purified PG and CL that were free of DNA, peptidoglycan, wall-teichoic acid, and lipoteichoic acid from A8819 cells (Fig. S8) were processed to form liposomes. Injection of the PG- and CL-specific liposomes into the otic-vesicle of zebrafish embryos showed that PG liposomes induced substantial neutrophil recruitment whereas the recruitment of neutrophils by CL liposomes was comparable to the PBS control (Fig. 5B,C). These data suggest that PG is the major bacterial-mediated phospholipid driver of neutrophil chemoattraction, and the *S. aureus* adaptation response to daptomycin represents a novel bacterial membrane

297 based stealth strategy to simultaneously evade an antibiotic and a key innate immune  
298 effector cell to promote survival within a host.  
299

## DISCUSSION

*S. aureus* has evolved a wealth of strategies to optimise its survival in various host niches and under nocuous selection pressures (30). Here, we report a new metabolic resistance mechanism used by *S. aureus* to prevent membrane lysis by the last line anti-staphylococcal antibiotic, daptomycin. Single amino acid substitutions in cardiolipin synthase 2 led to a significant increase in the bacterial membrane CL/PG ratios due to enhanced cardiolipin biosynthesis, which led to a thicker membrane that resisted daptomycin penetration and membrane disruption. Intriguingly, this adaption also led to immune evasion. Specifically, we showed that membrane PG acted as a bacterial-driven neutrophil chemoattractant and, in the context of *cls2* point mutations, reduced PG membrane content led to less neutrophil trafficking to a localized site of infection and prolonged bacterial survival.

Recent studies on the interactions between daptomycin and bacterial membranes have used indirect methodological approaches such as measuring permeability loss of liposomes exposed to daptomycin using a fluorescence assay, and membrane systems that are less relevant to Gram-positive bacteria, particularly using phosphatidylcholine (PC) and not L-PG (31). It was shown that the addition of cardiolipin to 10% of total lipids (using a PC/PG membrane system) was sufficient to prevent daptomycin interaction with membranes (31), however we have clearly shown that our daptomycin susceptible clinical strain (A8819) already has a greater percent of cardiolipin than 10% (Fig. 2A), suggesting the possibility of discordance between clinically relevant membranes. More recently, alteration of membrane curvature and diverting daptomycin binding, or interference with fluid membrane microdomains have been proposed using the model organism *Bacillus subtilis* or enterococcal strains (7, 32, 33). However, the phospholipid membrane composition of these organisms is different to *S. aureus*, and



daptomycin-membrane interactions appear to be bacterial-species dependent. For example, daptomycin has an irregular membrane binding pattern in *B. subtilis* and *Enterococcus*, with a particular predilection for the division septum (7, 32, 33), whereas we have observed universal distribution of daptomycin on *S. aureus* membranes (Fig. S6C-D).

Here, we have reconstituted clinically relevant *S. aureus* membranes and have provided the first direct structural analysis of daptomycin-membrane interactions. The scattering of free neutrons by matter provides excellent structural detail and this experimental approach has only recently been used to study biological membranes (25, 34). We used unsaturated phospholipids with complex head group composition to reconstitute the membranes, and the surface coverage achieved for the wild-type membranes was 86.5% (Table 1), which is higher than what has been previously reported using unsaturated phospholipids with similar techniques (35). Using SANS and NR, we identified three distinct modes of action of daptomycin on the membrane. At lower concentrations (2  $\mu\text{g/ml}$ ), lipid extraction occurred and caused lesions in the bilayer membrane, whereas at higher concentrations (4  $\mu\text{g/ml}$ ), daptomycin molecules penetrated into the bilayer and formed organised micelles. At the highest concentrations (8  $\mu\text{g/ml}$ ), the bilayer was completely solvated by daptomycin. The process of lipid extraction, penetration, micelle formation and membrane lysis was inhibited in the context of the clinically derived Cls2 amino acid substitution T33N, which coincided with daptomycin resistance. Interestingly, the daptomycin molecules still attached to the outer leaflet of the membrane in the A8819<sub>ClS2T33N</sub> strain, and this was corroborated with super-resolution imaging of fluorescent daptomycin binding to bacterial cells, but the daptomycin was functionally impaired due to the barrier created by the thicker CL-rich membrane. This is an anionic phospholipid driven mechanism of daptomycin resistance

and is independent of the charge-based repulsion theory proposed for *mprF* mutations that alter L-PG membrane content (4, 12).

Subversion of host immune surveillance contributes to persistent bacterial infections (36). Given the importance of neutrophils in eliminating *S. aureus* (15), we utilized a transgenic zebrafish line carrying red fluorescent neutrophils to characterize the interactions between *S. aureus* and neutrophils *in vivo* and in real-time during acute infection. We found that infection with the *S. aureus* *cls2* point mutants compromised neutrophil recruitment and this was associated with a more prolonged bacterial burden in the host. This compromised neutrophil migration was further confirmed using human neutrophils. The purified PG and CL liposomes used for the neutrophil migration studies were found to be free of DNA, peptidoglycan, lipoteichoic acids and wall-teichoic acids (Fig. S8), suggesting that established bacterial driven neutrophil chemoattractants for compromised neutrophil migration were not at play (37). We then focused on the phospholipid membrane components and through injection of purified CL and PG liposomes into zebrafish, established that PG was a driver for neutrophil chemotaxis. This provided a mechanistic model whereby *Cls2* amino acid substitutions led to increased cardiolipin synthase activity and increased CL production that was subsequently causing a reduction in PG. This change in lipid profile not only disturbed daptomycin-membrane interactions, but also reduced neutrophil chemoattraction to a localized site of infection, finally resulting in a more persistent infection, which has been observed in patients and animal models without a clear explanation (2, 5, 6). Future analyses are still required to investigate the generalization of bacterial PG in inducing neutrophil migration and if PG acts directly as a chemotactic or indirectly via activation of endogenous cells. In conclusion, we have characterised a bacterial metabolic adaptation process that leads to simultaneous evasion of host immune and

antimicrobial attack, providing important insights for future therapeutic targeting for this troublesome pathogen.

## Materials and Methods

### Media and reagents

Bacterial strains, plasmids, and oligonucleotides used in this study are described in Table S6. *S. aureus* and *Escherichia coli* cells were cultured in heart infusion broth (HI) (Oxoid) and Luria-Bertani broth with constant shaking at 37 °C, respectively.

### Genetic manipulation

The vector pIMAY and the *Escherichia coli* strain DC10B were used to genetically manipulate *S. aureus* isolate A8819 following the published protocol (SI Materials and Methods) (38).

### Daptomycin susceptibility testing

Broth microdilution MIC testing was performed based on guidelines by the Clinical and laboratory standards institute (CLSI). Daptomycin MIC > 1 µg/ml is officially termed daptomycin-nonsusceptible, but was termed daptomycin resistant throughout the manuscript for clarity. Time-kill assays were performed with an initial bacterial inoculum of 10<sup>6</sup> CFU/ml in Mueller-Hinton broth supplemented with 50 mg/litre calcium and daptomycin. (SI Materials and Methods).

### Lipid analysis by mass spectrometry

Lipids were extracted and analysed using thin-layer chromatography following the published protocol (10). Lipid species were processed and quantified according to standard procedures (39). For *de novo* phospholipid biosynthesis, the metabolic

labelling was initiated by the addition of glycerol or [ $^{13}\text{C}$ ]-glycerol (Sigma-Aldrich) to 1 mM after bacterial growth from optical density 600nm of 0.4 for 30 minutes at 37 °C. Data collected for lipid composition of PG, CL and L-PG with  $^{13}\text{C}$ -glycerol incorporation was analysed using Metaboanalyst (<http://www.metaboanalyst.ca>) (SI Materials and Methods).

#### ***S. aureus* bilayer membrane formation and neutron reflectometry (NR)**

Deposition of the model membrane on the top of a  $\text{SiO}_2$  surface was performed using a custom built Langmuir-Blodgett trough (Nima Technology, Coventry, UK) following published Langmuir-Blodgett (LB) and Langmuir-Schaefer (LS) procedures (22) (SI Materials and Methods). Synthetic PG (18:1), CL (18:1) and L-PG (18:1) (Avanti Polar Lipids, Inc) were mixed at the molar ratios of 69:12:19 and 23:60:17 to create A8819 and A8819<sub>CL2T33N</sub> symmetric membrane bilayers, respectively.

Specular neutron reflection at solid-liquid interface was carried out on the Platypus time-of-flight neutron reflectometer at the OPAL 20 MW Multi-purpose Research Reactor, Lucas Heights, Australia. The final reflectivity (reflected intensity / incident intensity) is presented as a function of momentum transfer. Analysis of the NR profiles was performed using MOTOFIT followed by Monte Carlo Analysis to determine 95% confidence intervals (40). (SI Materials and Methods).

#### **Small angle neutron scattering (SANS)**

Synthetic PG, CL and L-PG were mixed at the molar ratios of 69:12:19 and 23:60:17 for producing A8819 and A8819<sub>CL2T33N</sub> membrane vesicles respectively. The samples were measured using the small-angle neutron scattering instrument, Quokka, at ANSTO. (SI Materials and Methods).

430

431 **Zebrafish strains, maintenance and leukocyte enumeration**

432 Wild-type Tübingen and Tg(*lyz*:DsRed)<sup>nz50</sup> zebrafish (28) embryos were maintained in  
433 the Monash University Fish Core facility and infected with *S. aureus* cells according to  
434 standard protocols (27) (SI Materials and Methods).

435

436 ***In vitro* Transwell chemotaxis assay**

437 Human venous blood was collected from healthy volunteers for isolating neutrophils  
438 with the approval of the Monash University Human Research Ethics Committee.  
439 Chemotaxis assays were performed according to a previously published protocol (41)  
440 (SI Materials and Methods).

441

442 **Liposome preparation**

443 Staphylococcal PG or CL were extracted from TLC plates using  
444 chloroform/methanol/water (5:5:1) followed by centrifugation. Liposomes were  
445 prepared following an established protocol (42) (SI Materials and Methods).

446

447

448

449 **Acknowledgements**

450 We thank Monash Micro Imaging for the scientific and technical assistance; the  
451 Australian Center for Neutron Scattering, Australian Nuclear Science and Technology  
452 Organization (ANSTO) for providing the neutron research facilities. A.Y.P and B.P.H  
453 were funded by an Australian National Health and Medical Research Council (NHMRC)  
454 Practitioner Fellowship, and H.H.S. by a NHMRC Career Development Fellowship.  
455 G.J.L. is a NHMRC Senior Research Fellow. M.J.M is a NHMRC Principal Research

456 Fellow. The Abberior STED was funded by an ARC LIEF Grant (LE150100110, 2015).  
457 The Australian Regenerative Medicine Institute is supported by grants from the State  
458 Government of Victoria and the Australian Government.

459

460

461

462

## References

1. Lee AS, *et al.* (2018) Methicillin-resistant *Staphylococcus aureus*. *Nat Rev Dis Primers* 4:18033.
2. Fowler VG, Jr., *et al.* (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *The New England journal of medicine* 355(7):653-665.
3. Tran TT, Munita JM, & Arias CA (2015) Mechanisms of drug resistance: daptomycin resistance. *Annals of the New York Academy of Sciences* 1354:32-53.
4. Peleg AY, *et al.* (2012) Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of *Staphylococcus aureus*. *PloS one* 7(1):e28316.
5. Cameron DR, *et al.* (2015) Impact of daptomycin resistance on *Staphylococcus aureus* virulence. *Virulence* 6(2):127-131.
6. Richards RL, *et al.* (2015) Persistent *Staphylococcus aureus* isolates from two independent bacteraemia display increased bacterial fitness and novel immune evasion phenotypes. *Infection and immunity*.
7. Tran TT, *et al.* (2013) Daptomycin-resistant *Enterococcus faecalis* diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. *mBio* 4(4).
8. Ernst CM, *et al.* (2009) The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. *PLoS pathogens* 5(11):e1000660.
9. Peschel A, *et al.* (2001) *Staphylococcus aureus* resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. *The Journal of experimental medicine* 193(9):1067-1076.
10. Tsai M, *et al.* (2011) *Staphylococcus aureus* requires cardiolipin for survival under conditions of high salinity. *BMC microbiology* 11:13.
11. Koprivnjak T, *et al.* (2011) Characterization of *Staphylococcus aureus* cardiolipin synthases 1 and 2 and their contribution to accumulation of cardiolipin in stationary phase and within phagocytes. *Journal of bacteriology* 193(16):4134-4142.
12. Yang SJ, Mishra NN, Rubio A, & Bayer AS (2013) Causal role of single nucleotide polymorphisms within the *mprF* gene of *Staphylococcus aureus* in daptomycin resistance. *Antimicrobial agents and chemotherapy* 57(11):5658-5664.
13. Short SA & White DC (1972) Biosynthesis of cardiolipin from

501       phosphatidylglycerol in *Staphylococcus aureus*. *Journal of bacteriology*  
502       109(2):820-826.

503   14.   Spaan AN, Surewaard BG, Nijland R, & van Strijp JA (2013) Neutrophils versus  
504       *Staphylococcus aureus*: a biological tug of war. *Annual review of microbiology*  
505       67:629-650.

506   15.   Bogomolski-Yahalom V & Matzner Y (1995) Disorders of neutrophil function.  
507       *Blood reviews* 9(3):183-190.

508   16.   Wang R, *et al.* (2007) Identification of novel cytolytic peptides as key virulence  
509       determinants for community-associated MRSA. *Nature medicine* 13(12):1510-  
510       1514.

511   17.   Schiffmann E, Corcoran BA, & Wahl SM (1975) N-formylmethionyl peptides as  
512       chemoattractants for leucocytes. *Proceedings of the National Academy of*  
513       *Sciences of the United States of America* 72(3):1059-1062.

514   18.   Prat C, Bestebroer J, de Haas CJ, van Strijp JA, & van Kessel KP (2006) A new  
515       staphylococcal anti-inflammatory protein that antagonizes the formyl peptide  
516       receptor-like 1. *Journal of immunology* 177(11):8017-8026.

517   19.   de Haas CJ, *et al.* (2004) Chemotaxis inhibitory protein of *Staphylococcus*  
518       *aureus*, a bacterial antiinflammatory agent. *The Journal of experimental*  
519       *medicine* 199(5):687-695.

520   20.   Montange D, *et al.* (2014) Penetration of daptomycin into bone and synovial  
521       fluid in joint replacement. *Antimicrobial agents and chemotherapy*  
522       58(7):3991-3996.

523   21.   Traunmuller F, *et al.* (2010) Soft tissue and bone penetration abilities of  
524       daptomycin in diabetic patients with bacterial foot infections. *The Journal of*  
525       *antimicrobial chemotherapy* 65(6):1252-1257.

526   22.   Clifton LA, *et al.* (2013) Asymmetric phospholipid: lipopolysaccharide bilayers;  
527       a Gram-negative bacterial outer membrane mimic. *Journal of the Royal*  
528       *Society, Interface / the Royal Society* 10(89):20130810.

529   23.   Clifton LA, *et al.* (2015) Effect of divalent cation removal on the structure of  
530       gram-negative bacterial outer membrane models. *Langmuir : the ACS journal*  
531       *of surfaces and colloids* 31(1):404-412.

532   24.   Chen YF, Sun TL, Sun Y, & Huang HW (2014) Interaction of daptomycin with  
533       lipid bilayers: a lipid extracting effect. *Biochemistry* 53(33):5384-5392.

534   25.   Shen HH, Thomas RK, Penfold J, & Fragneto G (2010) Destruction and  
535       solubilization of supported phospholipid bilayers on silica by the biosurfactant  
536       surfactin. *Langmuir : the ACS journal of surfaces and colloids* 26(10):7334-  
537       7342.

538   26.   Hepburn L, *et al.* (2014) Innate immunity. A Spaetzle-like role for nerve



539 growth factor beta in vertebrate immunity to *Staphylococcus aureus*. *Science*  
540 346(6209):641-646.

541 27. Bhuiyan MS, *et al.* (2016) *Acinetobacter baumannii* phenylacetic acid  
542 metabolism influences infection outcome through a direct effect on  
543 neutrophil chemotaxis. *Proceedings of the National Academy of Sciences of*  
544 *the United States of America* 113(34):9599-9604.

545 28. Hall C, Flores MV, Storm T, Crosier K, & Crosier P (2007) The zebrafish  
546 lysozyme C promoter drives myeloid-specific expression in transgenic fish.  
547 *BMC developmental biology* 7:42.

548 29. Levraud JP, Colucci-Guyon E, Redd MJ, Lutfalla G, & Herbomel P (2008) In vivo  
549 analysis of zebrafish innate immunity. *Methods in molecular biology* 415:337-  
550 363.

551 30. Foster TJ, Geoghegan JA, Ganesh VK, & Hook M (2014) Adhesion, invasion and  
552 evasion: the many functions of the surface proteins of *Staphylococcus aureus*.  
553 *Nature reviews. Microbiology* 12(1):49-62.

554 31. Zhang T, *et al.* (2014) Cardiolipin prevents membrane translocation and  
555 permeabilization by daptomycin. *The Journal of biological chemistry*  
556 289(17):11584-11591.

557 32. Muller A, *et al.* (2016) Daptomycin inhibits cell envelope synthesis by  
558 interfering with fluid membrane microdomains. *Proceedings of the National*  
559 *Academy of Sciences of the United States of America*.

560 33. Pogliano J, Pogliano N, & Silverman JA (2012) Daptomycin-mediated  
561 reorganization of membrane architecture causes mislocalization of essential  
562 cell division proteins. *Journal of bacteriology* 194(17):4494-4504.

563 34. Clifton LA, *et al.* (2015) An accurate in vitro model of the *E. coli* envelope.  
564 *Angewandte Chemie* 54(41):11952-11955.

565 35. Hughes AV, *et al.* (2014) High coverage fluid-phase floating lipid bilayers  
566 supported by omega-thiolipid self-assembled monolayers. *Journal of the*  
567 *Royal Society, Interface / the Royal Society* 11(98):20140245.

568 36. Monack DM, Mueller A, & Falkow S (2004) Persistent bacterial infections: the  
569 interface of the pathogen and the host immune system. *Nature reviews.*  
570 *Microbiology* 2(9):747-765.

571 37. Schmeling DJ, *et al.* (1979) Chemotaxis by cell surface components of  
572 *Staphylococcus aureus*. *Infection and immunity* 26(1):57-63.

573 38. Monk IR, Shah IM, Xu M, Tan MW, & Foster TJ (2012) Transforming the  
574 untransformable: application of direct transformation to manipulate  
575 genetically *Staphylococcus aureus* and *Staphylococcus epidermidis*. *mBio*  
576 3(2).

- 577 39. Hu C, *et al.* (2008) RPLC-ion-trap-FTMS method for lipid profiling of plasma:  
578 method validation and application to p53 mutant mouse model. *Journal of*  
579 *proteome research* 7(11):4982-4991.
- 580 40. Nelson A (2006) Co-refinement of multiple-contrast neutron/X-ray reflectivity  
581 data using MOTOFIT. *Journal of Applied Crystallography* 39:273-276.
- 582 41. Corriden R, *et al.* (2008) Ecto-nucleoside triphosphate diphosphohydrolase 1  
583 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released  
584 ATP to adenosine. *The Journal of biological chemistry* 283(42):28480-28486.
- 585 42. Hope MJ, Bally MB, Webb G, & Cullis PR (1985) Production of large  
586 unilamellar vesicles by a rapid extrusion procedure: characterization of size  
587 distribution, trapped volume and ability to maintain a membrane potential.  
588 *Biochimica et biophysica acta* 812(1):55-65.

589

590

## Figure Legends

**Fig. 1.** Impact of Cls2 amino acid substitutions on daptomycin killing and resistance emergence. (A) The predicted amino acid change in Cls2 by individual *cls2* point mutations. N: amino-terminus. C: carboxyl-terminus. TM: transmembrane domain. PLD: phospholipase D domain. (B) Time-kill analyses showing quantitative bacterial counts during exposure to 2 µg/ml daptomycin. Dashed line indicates the detection limit. Comparison of the area under the curve between mutants and wild-type by one-way ANOVA (\* $P < 0.05$ , \*\* $P < 0.01$ ). (C) Daptomycin MIC of staphylococcal cells at each time point from the time-kill analysis. Error bars represent mean  $\pm$  SEM, three independent experiments.

**Fig. 2.** Impact of *cls2* point mutations on membrane phospholipid profiles. (A) The molar ratio of PG, CL, and L-PG among total phospholipids determined by LC-MS. (B) Repair of Cls2 T33N (T33NN33T) restored membrane phospholipid profiles to wild-type levels. Phospholipid biosynthesis was assessed after treatment with  $^{13}\text{C}$ -glycerol. (C) The ratios of  $^{13}\text{C}$ -CL, (D)  $^{13}\text{C}$ -PG and (E)  $^{13}\text{C}$ -L-PG (all isotopomers) among total lipid content were determined by LC-MS. Mean  $\pm$  SD, three independent experiments. \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$ , one-way ANOVA. n.s. non-significant. Student's *t* test was used to compare T33N to WT (C-E).

**Fig. 3.** Daptomycin-membrane interactions. The neutron reflectivity profiles (symbols) and fits (lines) of A8819 (A) and A8819<sub>Cls2T33N</sub> (B) membrane models in D<sub>2</sub>O and H<sub>2</sub>O are shown. The NR profiles in H<sub>2</sub>O are offset for clarity. The arrows indicate fringe shifts of NR profiles. The molecular models of reconstituted A8819 (C) and A8819<sub>Cls2T33N</sub> (D) membranes show a thicker, but more CL-rich membrane structure

(with CL in yellow, PG in red, and L-PG in blue). Small angle neutron scattering profiles measured for A8819 (*E*) and A8819<sub>Cl<sub>s</sub>2T33N</sub> (*F*) membranes treated with and without daptomycin (4 μg/ml). The arrow indicates the lipid bilayer whilst the star indicates the Bragg peak as the sign of micelle formation.

**Fig. 4.** Impact of Cls2 amino acid substitutions on neutrophil recruitment. (*A*) Schematic of a 48 h post-fertilization (hpf) zebrafish showing the *S. aureus* injection sites. Rectangle: somatic muscle. White circle: the otic vesicle. Scale bar = 250 μm. (*B*) Representative images of localized sites of infection with *S. aureus* strains at 6 h post-infection. (*C*) The number of emigrated neutrophils to the localized site of infection. For WT, n = 22; A23V, n = 29; T33N, n = 34; L52F, n = 27, pooled from four independent experiments. (*D*) Neutrophil recruitment was restored to wild-type levels by the repaired strain A8819<sub>Cl<sub>s</sub>2T33NN33T</sub>. For PBS, n = 12; WT, n = 21; T33N, n = 22; T33NN33T, n = 23, pooled from three independent experiments. (*E*) The bacterial burden in zebrafish after a somatic muscle infection. Error bars represent mean + SEM, three independent experiments ( $***P < 0.001$  compared to WT and T33NN33T, chi-square test for trend). (*F*) Human neutrophil recruitment was assessed using a Transwell system, with neutrophils and bacterial cells in the top and bottom wells respectively. Five independent experiments. For (*C*, *D*, and *F*), error bars represent mean ± SEM.  $*P < 0.05$ ,  $***P < 0.001$  compared to WT, Kruskal-Wallis test.

**Fig. 5.** Impact of bacterial membrane phospholipids on neutrophil migration *in vivo*. (*A*) Quantification of emigrated neutrophils into the zebrafish otic vesicle at 6 h after injection of liposomes constituted from *S. aureus* membrane phospholipids. For PBS,

640 n = 14; WT, n = 28; A23V, n = 26; T33N, n = 24; L52F, n = 24; T33NN33T, n = 17,  
641 pooled from four independent experiments. (B) Representative images of zebrafish otic  
642 vesicles (red circles) injected with purified PG or CL liposomes, with quantification of  
643 emigrated neutrophils (C). For PBS, n = 10; PG, n = 17; CL, n = 17, pooled from three  
644 independent experiments. Error bars represent the mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$   
645 and \*\*\* $P < 0.001$  compared to PBS for (A) and (C), one-way ANOVA.

646

647

648